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Objectives: Recent research has confirmed the presence of aluminium in human brain tissue. Quantitative analyses
suggest increased brain aluminium content in a number of neurodegenerative diseases including familial Alz-
heimer's disease, congophilic amyloid angiopathy, epilepsy and autism. Complementary aluminium-specific
fluorescence microscopy identifies the location of aluminium in human brain tissue and demonstrates signifi-
cant differences in distribution between diseases. Herein we combine these approaches in investigating associ-
ations between aluminium in human brain tissue and specific disease-associated neuropathologies.
Methods: We have used aluminium-specific fluorescence microscopy, Congo red staining using light and polarised
light and thioflavin S fluorescence microscopy on serial sections of brain tissues to identify co-localisation of
aluminium and amyloid β and tau neuropathology.
Results: A combination of light, polarised and fluorescence microscopy demonstrates an intimate relationship
between aluminium and amyloid β in familial Alzheimer's disease but not in other conditions and diseases, such as
congophilic amyloid angiopathy and autism. We demonstrate preliminary evidence of amyloid β pathology,
including associations with vasculature and parenchymal tissues, in autism in tissues heavily loaded with
aluminium.
Conclusion: We suggest that complementary aluminium-specific fluorescence microscopy may reveal important
information about the putative toxicity of aluminium in neurodegenerative and neurodevelopmental disorders.1. Introduction
Human exposure to aluminium is increasing [1]. A burgeoning body
burden of an element that is only inimical to human health must be a
concern [2]. The Aluminium Age has rendered human exposure as
inevitable (https://www.hippocraticpost.com/mens-health/the-alumini
um-age/). The workplace is no exception and in some circumstances
may represent an accelerated exposure to aluminium [3, 4, 5]. The brain
is a major target of aluminium intoxication [6, 7]. Aluminium is present
in human brain tissue [8]. A burgeoning database documents its content
in brain tissue from a variety of donors including those without
discernible neuropathology to individuals who died with a recognised
neurodegenerative disease or neurodevelopmental disorder [9]. Mea-
surements of absolute amounts of aluminium in brain tissue have allowed
the establishment of toxicity thresholds and confirmed long held un-
derstanding that its distribution is focal and likely associated with spe-
cific neuropathologies. The data document the presence of aluminium in
all brain regions studied and, in general, do not identify any lobe-specific
accumulations. However, these important quantitative determinations oform 16 March 2020; Accepted 21
evier Ltd. This is an open access acontent are now complemented with aluminium-specific fluorescence
microscopy [10] showing the exact location of aluminium in human
brain tissue. When combined with standard microscopy methods to
identify disease neuropathology such as amyloid β and tau these com-
plementary data are proving useful and revealing in equating the pres-
ence of aluminium with its toxicity and potential contribution to disease
aetiology. Herein we combine aluminium-specific fluorescence micro-
scopy with other forms of light and fluorescence microscopy to reveal
co-relationships between aluminium deposition and the neuropathology
of a number of neurodegenerative diseases and neurodevelopmental
disorders.
2. Materials and methods
2.1. Tisssues
All tissues studied herein were provided as prepared slides by brain
banks following ethical approval. Details of the latter are available in
each of the cited source publications.April 2020
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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All chemicals were purchased from Sigma Aldrich unless otherwise
stated. Brain tissue sections were dewaxed using the d-limonene based
reagent Histo-Clear (National Diagnostics, US) and rehydrated through
an ethanol gradient into ultrapure water (conductivity <0.067 μS/cm).
Rehydrated tissue sections were subsequently outlined with a hydro-
phobic PAP pen for staining, allowing for staining to be performed in
humidity chambers using low reagent volumes (200μL).
2.3. Lumogallion staining for the detection of aluminium
Rehydrated serial brain tissue sections were incubated in humidity
chambers for 45 min in 1mM lumogallion (4-chloro-3-(2,4-dihydrox-
yphenylazo)-2-hydroxybenzene-1-sulphonic acid, TCI Europe N.V.
Belgium) prepared in 50mM PIPES buffer (1,4-Piper-
azinediethanesulphonic acid), pH 7.4. Sections for autofluorescence were
incubated in the buffer only and staining was performed at ambient
temperature away from light. Following staining, sections were washed
with fresh 50mM PIPES buffer, pH 7.4 and rinsed for 30s in ultrapure
water. Sections were mounted with the aqueous mounting medium
Fluoromount™ under glass coverslips.
2.4. Congo red staining for the detection of amyloid β
Rehydrated sections for Congo red staining were immersed in 0.5%
w/v Congo red in 50% v/v ethanol for 5 min at ambient temperature.
Sections were subsequently differentiated via immersion in 0.2% w/v
potassium hydroxide prepared in 80% v/v ethanol for 3 s and washed for
30 s in ultrapure water. Stained sections were subsequently mounted
using the aqueous mounting medium Faramount (Agilent Dako, UK)
under glass coverslips.
2.5. Thioflavin S staining for the detection of amyloid β
Thioflavin S (ThS) staining was performed in humidity chambers via
the addition of ca 0.075% w/v ThS, prepared in 50% v/v ethanol to
rehydrated and PAP pen outlined brain tissue sections for 8 min. Staining
was performed at ambient temperature away from light. Following
staining, slides were immersed twice for 10 s in fresh solutions of 80% v/
v ethanol. Sections were subsequently washed and agitated in ultrapure
water for 30 s. Sections stained in this way were mounted with
Fluoromount™.
2.6. Fluorescence and light microscopy
All microscopy was performed by use of an Olympus BX50 fluores-
cence microscope equipped with a vertical illuminator and BX-FLA re-
flected light attachment (mercury source). Lumogallion fluorescence and
respective autofluorescence were captured using a U-MNIB3 fluores-
cence filter cube (excitation filter: 470–495nm, dichromatic mirror:
505nm, longpass barrier filter: 510nm). ThS fluorescence was captured
using a U-MWBV2 filter cube (excitation filter: 400–440nm, dichromatic
mirror: 455nm, longpass barrier filter: 475nm). All fluorescence filter
cubes were from Olympus, UK. Congo red staining was visualised under
brightfield illumination and polarised light using a U-POT polariser and a
U-ANT transmitted light analyser (both from Olympus, UK). Images were
acquired using a ColorView III CCD camera and the CellD software suite
(Olympus, SiS Imaging Solutions, GmbH).
3. Results
3.1. Aluminium and cerebral amyloid angiopathy
An earlier observation of a high content of brain aluminium coinci-
dent with a rare form of sporadic early onset cerebral amyloid2angiopathy (CAA) suggested that amyloid β and aluminium might be co-
localised in this tissue [11]. The case showed severe widespread con-
gophilic angiopathy in cerebral cortical and leptomeningeal vessels.
There were no senile plaques and few neurofibrillary tangles. CAA was
widespread throughout brain tissue, with the exception of the hippo-
campus, as identified by positive Congo red staining and apple green
birefringence under polarised light (Figure 1A). Congo red-positive
spherulites under polarised light showed classical Maltese cross diffrac-
tion patterns and occasional apple-green birefringence (Figure 1B).
While lumogallion fluorescence identified aluminium in all tissues
examined, aluminium was not co-located with extracellular deposits of
amyloid β [12]. Indeed the majority of aluminium deposits were intra-
cellular and associated with glia-like cells including microglia and as-
trocytes (Figure 1C,D). Aluminium was in lymphocyte-like cells and cells
lining the choroid plexus. Some deposits of aluminium were intra-
neuronal and there were a number of extracellular deposits of aluminium
often surrounded by aluminium-loaded glia. Critically while amyloid β
was unerringly extracellular and associated with vasculature aluminium
deposits were almost exclusively intracellular.
3.2. Aluminium and epilepsy
We recently reported the first quantitative data on aluminium in
human brain tissue in epilepsy [13]. The analyses showed high concen-
trations of aluminium in two areas of the brain, occipital lobe and hip-
pocampus, known to be affected in epilepsy. Qualitative imaging by
aluminium-specific fluorescence fully supported the quantitative data
and especially in the hippocampus where a consistent observation was
non-specific aluminium-rich cellular debris surrounded by
aluminium-loaded glia-like cells (Figure 2A). Congo red failed to identify
amyloid β in any tissue while ThS revealed intracellular and extracellular
tau in neurofibrillary tangle-like deposits in all tissues though without
evidence of co-localisation with aluminium (Figure 2B).
3.3. Aluminium and autism
While there are data for very few donors, the aluminium content of
brain tissue in autism is invariably very high and especially in the light of
the young age of donors [14]. However, the stand-out, and at the time
unique, observation in autism brain tissues was the almost exclusive
intracellular, non-neuronal location of aluminium deposits. While
aluminium was found associated with extracellular, probably neuronal,
debris as well as being located in some neuronal bodies it was primarily
found as membrane-bound deposits in non-neuronal cells including
microglia and lymphocytes (Figure 3A,B). In an attempt to relate ob-
servations of aluminium with potential neuropathology, we have iden-
tified amyloid β-like deposits in autism brain tissue and examined its
potential relationship with aluminium. Future research using immuno-
labelling is required to confirm unequivocally that the observed deposits
are amyloid β and not some other form of amyloid.
Amyloid β was positively identified using both Congo red and thio-
flavin S throughout donor tissues. A consistent observation was amyloid
β, exhibiting apple-green birefringence under polarised light, associated
with vasculature. Amyloid β was confirmed using both methods in the
perivascular region of blood vessels and resembled classical cerebral
amyloid angiopathy (Figure 3C,D). Parenchymal deposits of amyloid β,
positive for both apple-green birefringence and ThS, were also observed
in hippocampal tissues of donors (Figure 3E,F). While both amyloid β and
aluminium were widely distributed throughout these brain tissues, there
were very few instances where there was evidence of co-localisation.
3.4. Aluminium and familial Alzheimer's disease
Some of the highest concentrations of aluminium ever measured in
human brain tissue were recorded in donors with a diagnosis of familial
Alzheimer's disease (fAD) [15]. Initial investigations suggested that the
Figure 1. Amyloid β and aluminium deposi-
tion in brain tissue of a 59-year-old female
donor with cerebral amyloid angiopathy
(CAA). (A)Congo red reactive amyloid β was
identified in leptomeningeal vessels in the
parietal lobe by a red hue that produced
apple-green birefringence under polarised
light (magnified insert) and occasionally as
spherulites as revealed by Maltese cross
diffraction patterns, in the same lobe (B).
Intracellular aluminium (orange) in microglia
surrounding astrocytes (C) and appearing as
punctate deposits within astrocytes (D), in
cortical and white matter regions, respec-
tively (asterisks denote magnified inserts).
Figure adapted from [12] under CC license.
Bars ¼ (A): 200μm (B - D): 50μm.
Figure 2. Intracellular aluminium and neurofibrillary tangles in brain tissue of
a 60-year-old male donor with epilepsy. (A) Aluminium (orange) rich cellular
debris surrounded by aluminium-loaded glial cells in the parahippocampal
gyrus. (B) No lumogallion-reactive aluminium was identified in the parietal lobe
and instead, cortical thioflavin S (ThS) positive neurofibrillary tangles (green)
were observed (magnified inserts are denoted by asterisks). Figure adapted from
[13] under CC license. Bars ¼ 50μm.
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3majority of aluminium deposits were extracellular with a tentative sug-
gestion of an association with β amyloid. A close relationship between
aluminium and amyloid β in fAD is now confirmed with myriad examples
throughout all donor tissues [16]. The co-localisation of aluminium and
amyloid β in senile plaques was especially evident (Figure 4) and there
were also examples of cerebral amyloid angiopathy exhibiting
co-deposits of aluminium and apple-green birefringent positive amyloid
β. ThS additionally identified neurofibrillary tangles in these tissues some
in the immediate vicinity of aluminium-rich senile plaques.
4. Discussion
In fAD, where there is a genetic predisposition resulting in a higher
body burden of amyloid β earlier in life [17], we observed intimate as-
sociations between deposits of aluminium and amyloid β in brain tissue
[16]. Tissues from all four main lobes of the brain included many senile
plaques and almost invariably, aluminium was co-located with these
structures (Figure 4). The intimacy of the co-localisations in many cases
suggested direct associations and even co-deposition of aluminium and
amyloid β. However, such immediate relationships cannot be confirmed
by microscopy. Cerebral amyloid angiopathy was also observed in many
of these tissues and was similarly accompanied by deposits of aluminium.
At first glance, these observations in fAD seem to present a primo facie
case for the co-deposition of amyloid β and aluminium in fAD. However,
in a case of aggressive, early onset CAA involving the exclusive deposi-
tion of amyloid β with the vasculature (no senile plaques) and very high
levels of brain tissue aluminium there were no clear associations between
these factors (Figure 1). Aluminium was not co-located with amyloid β in
this case of early onset sporadic AD with extensive CAA [11, 12]. We also
identified examples of CAA in autism brain tissue (Figure 3C,D) and
while these tissues were heavily loaded with aluminium (Figure 3A,B),
similarly to the aforementioned case of CAA we did not find evidence of
co-localisation of aluminium and amyloid β in either the vasculature or
other tissues in autism. In epilepsy, there was no evidence of amyloid β
anywhere in the brain and so no relationship with aluminium could be
tested. We have made the intriguing observation that in fAD where the
majority of deposits of aluminium were extracellular there were close
relationships between aluminium and amyloid β. However, in CAA and
autism where the majority of deposits of aluminium were intracellular,
Figure 3. Intracellular aluminium, CAA and
parenchymal amyloid β-like deposits in brain
tissue of donors diagnosed with autism. (A)
Aluminium-loaded (orange) microglial cell
surrounding extracellular aluminium rich
cellular debris in the temporal cortex of a 15-
year-old male donor. (B) Intracellular
aluminium in lymphocytes within lep-
tomeningeal membranes in the hippocampus
of a 50-year-old male donor. (C) Positive
Congo red staining indicative of CAA in a
cortical blood vessel in the frontal lobe a 14-
year-old male donor. (D) Positive thioflavin S
(ThS) staining (green) in the same cortical
blood vessel. Parenchymal deposits of Congo
red reactive amyloid in the hippocampus of
(E) 33 and (F) 22-year-old male donors
depicting apple-green birefringence in the
highlighted (asterisks) regions when viewed
under polarised light. Magnified inserts are
denoted by asterisks. A & B adapted from
[14] under CC license. Bars ¼ (A & B): 50 μm
(C - F): 100μm.
Figure 4. Aluminium co-localised with amyloid β in a senile plaque identified in the white matter of the parietal lobe of a donor diagnosed with familial Alzheimer's
disease (fAD). Lumogallion-reactive aluminium was identified via an orange fluorescence emission, co-localised with positive thioflavin S (ThS) staining (green) in the
lower magnified insert. Bar ¼ 50μm.
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parenchymal tissues. This raises the possibility that predispositions to an
increased body burden of amyloid β are also predispositions to the
co-localisation, perhaps even co-deposition, of aluminium and amyloid β
in brain tissue. The comparison with pure CAA (amyloid β only associ-
ated with vasculature) and autism may also suggest different routes of
entry of aluminium into brain tissue. For example, is a higher body
burden of amyloid β facilitating the entry of aluminium into brain tissue
in fAD. In pure CAA and autism, the preponderance of brain aluminium
deposits in non-neuronal intracellular compartments including glia and
lymphocytes suggests a role for diapedesis [18] in aluminium entry into
brain tissue. There is a long history identifying interactions between
aluminium and amyloid β, both in vitro and in vivo. The former support
amyloid β binding aluminium [19, 20, 21] while the latter have proposed
their co-localisation and especially in Alzheimer's disease [22, 23]. There
are no data to confirm binding of aluminium (or any metal cation) by
amyloid β in vivo (animal models or human) and the observations herein
are the first to suggest that while the association of aluminium with
amyloid β in vivo in humans is not inevitable it is possible, such as in fAD.
Our observations of amyloid β-like deposits in autism brain tissue are
novel and may suggest neuropathology similar to that seen in CAA. We
identified several examples of CAA in autism brain tissue as well as de-
posits of amyloid β in β sheet conformations in parenchymal tissues
(Figure 3C-F). Previous research identified diffuse deposits of amyloid β
in brain tissue in older individuals with autism (39 and 50 years of age)
[24] while herein amyloid β in β sheet conformations was confirmed in
individuals with autism aged, 14, 15, 22, 33, 44 and 50 years of age.
Recently the non-amyloidogenic pathway of metabolism of amyloid
precursor protein has been implicated in autism [25] while our obser-
vations suggest that the amyloidogenic pathway may also be important.
Tau pathologies and specifically neurofibrillary tangles (NFT) were
identified using ThS in epilepsy (Figure 2) and in fAD. While historically
aluminium has been shown to be co-located with tau in NFT we were
unable to demonstrate the co-localisation of aluminium and tau using
fluorescence microscopy.
Quantitative data demonstrating aluminium in brain tissues in
neurodegenerative disease has been helpful in implicating aluminium in
disease aetiology. Recent developments in aluminium-specific fluores-
cence microscopy have complemented quantitative data in providing
information pertaining to the location of aluminium in human brain
tissue. These novel observations now raise intriguing questions con-
cerning the relationship between amyloid β and aluminium in neurode-
generative disease and suggest an intimate association in fAD.
Declarations
Author contribution statement
Christopher Exley: Conceived and designed the experiments;
Analyzed and interpreted the data; Wrote the paper.
Matthew J Mold: Conceived and designed the experiments; Per-
formed the experiments; Analyzed and interpreted the data; Wrote the
paper.
Funding statement
This work was supported by the Children’s Medical Safety Research
Institute (CMSRI), a charity based in Washington DC, US and individual
donations to Keele University.
Competing interest statement
The authors declare no conflict of interest.5Additional information
No additional information is available for this paper.
Acknowledgements
MJM is a CMSRI Research Fellow. CE acknowledges the support of the
Oxford Brain Bank (15/SC/0639) and the brain bank of the Universidad
Antioquia, Medelin, Colombia (ERP2398) in providing tissues used in
this research.
References
[1] C. Exley, Human exposure to aluminium, Environ. Sci. Process Impacts 15 (2013)
1807–1816.
[2] C. Exley, The toxicity of aluminium in humans, Morphologie 100 (2016) 51–55.
[3] S. Polizzi, E. Pira, M. Ferrara, M. Bugiani, A. Papaleo, R. Albera, S. Palmi,
Neurotoxic effects of aluminium among foundry workers and Alzheimer’s disease,
Neurotoxicology 23 (2002) 761–774.
[4] M. Meyer-Baron, M. Schaper, G. Knapp, C. van Thiel, Occupational aluminium
exposure: evidence in support of its neurobehavioural impact, Neurotoxicology 28
(2007) 1068–1078.
[5] C. Exley, T. Vickers, Elevated brain aluminium and early onset Alzheimer’s disease
in an individual occupationally exposed to aluminium: a case report, J. Med. Case
Rep. 8 (2014) 41.
[6] S.C. Bondy, The neurotoxicity of environmental aluminium is still an issue,
Neurotoxicology 31 (2010) 575–581.
[7] C. Exley, Why industry propaganda and political interference cannot disguise the
inevitable role played by human exposure to aluminium in neurodegenerative
diseases including Alxheimer’s disease, Front. Neurol. 5 (2014) 212.
[8] C. Exley, E. House, Aluminium in the human brain, Monat. Chem.—Chem. Mon.
142 (2011) 357–363.
[9] C. Exley, M.J. Mold, Aluminium in human brain tissue: How much is too much?
J. Biol. Inorg. Chem. 24 (2019) 1279–1282.
[10] A. Mirza, A. King, C. Troakes, C. Exley, The identification of aluminium in human
brain tissue using lumogallion and fluorescence microscopy, J. Alzh. Dis. 54 (2016)
1333–1338.
[11] C. Exley, M. Esiri, Severe cerebral congophilic angiopathy coincident with increased
brain aluminium in a resident of Camelford, Cornwall, UK, J. Neurol. Neurosurg.
Psychiatry 77 (2006) 877–879.
[12] M. Mold, J. Cottle, A. King, C. Exley, Intracellular aluminium in inflammatory and
glial cells in cerebral amyloid angiopathy: a Case Report, Int. J. Environ. Res. Publ.
Health 16 (2019) 1459.
[13] M. Mold, J. Cottle, C. Exley, Aluminium in brain tissue in epilepsy: a case report
from Camelford, Int. J. Environ. Res. Publ. Health 16 (2019) 2129.
[14] M. Mold, D. Umar, A. King, C. Exley, Aluminium in brain tissue in autism, J. Trace
Elem. Med. Biol. 46 (2018) 76–82.
[15] A. Mirza, A. King, C. Troakes, C. Exley, Aluminium in brain tissue in familial
Alzheimer’s disease, J. Trace Elem. Med. Biol. 40 (2017) 30–36.
[16] M. Mold, C. Linhart, J. Gomez-Ramirez, A. Villegas-Lanau, C. Exley, Aluminium and
amyloid β in familial Alzheimer’s disease, J. Alzh. Dis. 73 (2020) 1627–1635.
[17] R. Sherrington, E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, Cloning of a gene
bearing missense mutations in early-onset familial Alzheimer’s disease, Nature 375
(1995) 754–760.
[18] J. Greenwood, S.J. Heasman, J.I. Alvarez, A. Prat, R. Lyck, B. Engelhardt,
Leucocyte–endothelial cell crosstalk at the blood–brain barrier: a prerequisite for
successful immune cell entry to the brain, Neuropathol. Appl. Neurobiol. 37 (2011)
24–39.
[19] C. Exley, N.C. Price, S.M. Kelly, J.D. Birchall, An interaction of β-amyloid with
aluminium in vitro, FEBS Lett. 324 (1993) 293–295.
[20] M. Turner, S.T. Mutter, O.D. Kennedy-Britten, J.A. Platts, Molecular dynamics
simulation of aluminium binding to amyloid-β and its effect on peptide structure,
PLoS One 14 (2019) e0217992.
[21] J.I. Mujika, J.R.G. Pedregal, X. Lopez, J.M. Ugalde, L.R. Santiago, M. Sodupeb, J.-
D. Marechal, Elucidating the 3D structures of Al(III)–Aβ complexes: a template free
strategy based on the pre-organization hypothesis, Chem. Sci. 8 (2017) 5041.
[22] S. Duckett, P. Galle, Electron microscope-microprobe studies of aluminium in the
brains of cases of Alzheimer's disease and aging patients, J. Neuropathol. Exp.
Neurol. 39 (1980) 350.
[23] L. Tomljenovic, Aluminium and Alzheimer’s disease: after a century of controversy
is there a plausible link? J. Alzh. Dis. 23 (2011) 567–598.
[24] J. Wegiel, J. Frackowiak, B. Mazur-Kolecka, N.C. Schanen, E.H. Cook Jr., et al.,
Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic
and Dup15q11.2-q13 autism spectrum disorders, PLoS One 7 (2012) e35414.
[25] D.K. Sokol, B. Maloney, C.J. Westmark, D.K. Lahiri, Novel contribution of secreted
amyloid-precursor protein to white matter brain enlargement in autism spectrum
disorder, Front. Psychiatr. 10 (2019) 165.
